Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- FPMAJ Not Giving Up on Perpetuation of Premium for New Drug Development: Committee Chair
April 9, 2014
- MHLW, MEXT, and METI Map Out New 10-Year Strategy for Cancer Research
April 8, 2014
- Ministry Panel Starts Reviewing Five-Year Promotion Plan for Clinical Research
April 8, 2014
- Japan NIH to Kick in with 300 Workers, 200 of Them on Contract
April 7, 2014
- Novartis’ Cover-Up Attempt over SIGN Trial “Outrageous”: Minister
April 7, 2014
- PMDA Opens New Office to Prepare for Introduction of CDISC Standards
April 4, 2014
- MHLW Sets New Target Review Periods for Diagnostics to Speed up Regulatory Processes
April 2, 2014
- PMDA to Boost Workforce to 1,065 in Five Years
April 2, 2014
- MHLW to Set Up Council on Measures Against Counterfeit Drugs with Lifting of Ban on Online OTC Drug Sales
April 2, 2014
- PMDA to Conduct Pharmacokinetic Analysis in Pilot Study on Electronic NDA Submissions
April 1, 2014
- Lower House Panels to Begin Deliberations on Japanese NIH-Related Bills
April 1, 2014
- PMDA Announces Results of Pilot Study on Electronic NDA Submissions Using CDISC Standards
April 1, 2014
- Mixed Care to Be Boosted in Tokyo, Kansai Special Economic Zones: Panel
March 31, 2014
- Govt Deregulation Panel Pushes New System to Allow Mixed Care at Patient Request
March 31, 2014
- MHLW to Set Up Study Group on Clinical Research Legislation in April: Minister Tamura
March 31, 2014
- Science Council of Japan Recommends Establishment of Clinical Research Promotion Center at PMDA
March 31, 2014
- Fulminant Hepatitis Added to Precautions Section of Package Insert for Regorafenib: MHLW Safety Information
March 31, 2014
- MHLW Panel Concludes Novartis Systematically Involved in Diovan Trials: Report
March 28, 2014
- Drug-Induced Hypersensitivity Syndrome to Be Added to List of Clinically Significant Adverse Reactions for E Keppra: MHLW
March 28, 2014
- FY2014 Medical Fee Revision Expected to Shift Outpatient Care Functions from Large Hospitals to Smaller Hospitals and Clinics, Alter Patient Behavior and Prescription Patterns
March 28, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…